| Migraine |
1 |
1 |
| Tryptamine |
0 |
0.62 |
| Adverse Effects |
0 |
0.54 |
| Nonsteroidal Anti-Inflammatory Agents |
0 |
0.51 |
| Cardiovascular Risk Management |
0 |
0.26 |
| Pain Management |
0 |
0.99 |
| Patient Safety |
0 |
0.24 |
| Blood |
0 |
0.23 |
| Headache |
0 |
0.23 |
| Blood Vessel |
0 |
0.22 |
| Increased Blood Pressure |
0 |
0.22 |
| Hypertension |
0 |
0.19 |
| Nausea |
0 |
0.15 |
| Toxicology |
0 |
0.15 |
| Uncontrolled Hypertension |
0 |
0.15 |
| Washington DC |
0 |
0.11 |
| Cerebrovascular Accident |
0 |
0.09 |
| Myocardial Infarction (MI) |
0 |
0.09 |
| Body Mass Index |
0 |
0.08 |
| Disability |
0 |
0.08 |
| Dizziness |
0 |
0.08 |
| Europe |
0 |
0.08 |
| Exercise |
0 |
0.08 |
| Hospital |
0 |
0.08 |
| Insurance |
0 |
0.08 |
| Meditation |
0 |
0.08 |
| Monoclonal Antibody |
0 |
0.08 |
| Neurostimulation |
0 |
0.08 |
| Pain |
0 |
0.08 |
| Smoking |
0 |
0.08 |
| Spain |
0 |
0.08 |
| Statins |
0 |
0.08 |
| Stress |
0 |
0.08 |
| Surgery |
0 |
0.08 |
| Travel Medicine |
0 |
0.08 |
| Washington |
0 |
0.08 |
| Revenue and Practice Management |
0 |
0.06 |